A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 431
- 试验地点
- 39
- 主要终点
- Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) at One Year
研究概览
简要总结
1703: The study is designed as a randomized, phase III, multicenter trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens: tacrolimus/methotrexate (Tac/MTX) versus post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil (PTCy/Tac/MMF) in the setting of reduced intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation.
1801: The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced intensity allogeneic HCT.
详细描述
1703: Graft-versus-Host Disease (GVHD) is a complication that affects many hematopoietic stem cell transplant (HSCT) patients; it occurs when the new cells from a transplant attack the recipient's body. The current standard GVHD prophylaxis regimen for patients with hematologic malignancies undergoing HSCT involves a combination of immunosuppressive agents given for the first 6 months after transplant.
The standard strategy of Tacrolimus/Methotrexate will be used as a control arm in comparison to one other treatment plan utilizing Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide. Study participants will receive an infusion of mobilized peripheral blood stem cell grafts on both arms. Study participants will be randomized to one of these two treatment arms.
1801: A relationship between the intestinal microbiota and graft-versus-host disease (GVHD) has long been appreciated but is still not well understood. Mice transplanted in germ-free conditions or treated with gut-decontaminating antibiotics developed less severe GVHD. Clinical studies initially suggested a benefit from near-total bacterial decontamination, but later showed no clear benefit and this approach was discontinued in the early 1990s. Partial gut decontamination continues to be practiced at many centers. More recently, the advent of next-generation sequencing (NGS) has resulted in cheaper and easier characterization of complex microbial mixtures. This has led to a renewed interest in evaluating the relationship between the microbiota and human health and disease, including recipients of hematopoietic cell transplantation (HCT). Similarly, NGS has also contributed to significant advancements in the investigator's understanding of immune reconstitution in HCT patients and how this may impact clinica outcomes.
The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced intensity allogeneic HCT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18.0 years or older at the time of enrollment on Segment A
- •Patients with acute leukemia or chronic myelogenous leukemia with no circulating blasts and with less than 5% blasts in the bone marrow
- •Patients with myelodysplasia/chronic myelomonocytic leukemia with no circulating blasts and with less than 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with <5% vs. 5-10% blasts in this disease)
- •Patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma with chemosensitive disease at time of transplantation
- •Patients with lymphoma [follicular lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma] with chemosensitive disease at the time of transplantation
- •Planned reduced intensity conditioning regimen (see eligible regimens in Table 2.4a)
- •Patients must have a related or unrelated peripheral blood stem cell donor as follows:
- •Sibling donor must be a 6/6 match for Human Leukocyte Antigen-A (HLA)-A and -B at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing, and must be willing to donate peripheral blood stem cells and meet institutional criteria for donation.
- •Unrelated donor must be a 7/8 or 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be willing to donate peripheral blood stem cells and meet National Marrow Donor Program (NMDP) criteria for donation.
- •Cardiac function: Left ventricular ejection fraction at least 45%
- •Estimated creatinine clearance acceptable per institutional guidelines
- •Pulmonary function: Diffusing capacity of lung for carbon monoxide (DLCO) corrected for hemoglobin at least 40% and forced expiratory volume at one second (FEV1) predicted at least 50%
- •Liver function acceptable per institutional guidelines
- •Karnofsky Performance Score at least 60%
- •Female patients (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months post-transplant (see Section 2.6.4 for definition of postmenopausal)
- •Male patients (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception (see Section 2.6.4 for list of barrier methods), or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant
- •Plans for the use of post-transplant maintenance therapy must be disclosed upon enrollment and must be used irrespective of the outcome of the randomization. Please note that THIS DOES NOT INCLUDE INVESTIGATIONAL AGENTS and maintenance therapy with investigational treatment requires approval by the study chairs.
- •Voluntary written consent obtained prior to the performance of any study-related procedure that is not a part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
排除标准
- •Prior allogeneic transplant
- •Active central nervous system (CNS) involvement by malignant cells
- •Patients with secondary acute myeloid leukemia arising from myeloproliferative disease, including chronic myelomonocytic leukemia (CMML)
- •Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.
- •Presence of clinically significant fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
- •Patients seropositive for human immunodeficiency virus (HIV) with detectable viral load. HIV+ patients with an undetectable viral load on antiviral therapy are eligible.
- •Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
- •Female patients who are pregnant (as per institutional practice) or lactating
- •Patients with a serious medical or psychiatric illness likely to interfere with participation in this clinical study
- •Patients with prior malignancies except resected non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously must be reviewed and approved by the Protocol Officer or Chairs.
- •Planned use of antithymocyte globulin (ATG) or alemtuzumab in conditioning regimen
研究组 & 干预措施
Tacrolimus/Methotrexate
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
干预措施: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate (Procedure)
Tacrolimus/Methotrexate
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
干预措施: Tacrolimus (Drug)
Tacrolimus/Methotrexate
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
干预措施: Methotrexate (Drug)
Tacrolimus/MMF/PTCY
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
干预措施: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide (Procedure)
Tacrolimus/MMF/PTCY
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
干预措施: Tacrolimus (Drug)
Tacrolimus/MMF/PTCY
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
干预措施: Mycophenolate Mofetil (Drug)
Tacrolimus/MMF/PTCY
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
干预措施: Cyclophosphamide (Drug)
结局指标
主要结局
Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) at One Year
时间窗: 1 year post randomization
The primary endpoint is GRFS as a time to event endpoint from randomization. All randomized patients will be followed for one year; however, the primary endpoint will be analyzed as a time to event endpoint. The primary analysis will be done using the randomized population. An event for this time to event outcome is defined as grade III-IV acute GVHD, chronic GVHD requiring systemic immune suppression, disease relapse or progression, or death by any cause, whichever comes first. Time to event analyses were conducted. An unadjusted Kaplan-Meier analysis was done. Additionally, a multivariate Cox regression model adjusting for the following pre-specified covariates: age group (\< 65 vs. 65+), disease risk index (low, intermediate, high/very high), planned RIC conditioning regimen (Fludarabine/Busulfan, Fludarabine/Melphalan, Other), donor type/HLA matching score (related 6/6, unrelated 7/8, unrelated 8/8), and planned use of post-transplant maintenance therapy (Yes vs. no).
次要结局
- Participants With Maximum Stage of Skin, Lower GI, and Liver at Day 100 Post-transplant(Day 100 post-transplant)
- Frequencies of Infections Categorized by Infection Type(1 year post-transplant)
- Percentage of Participants With Grades II-IV and III-IV Acute GVHD at Day 100 Post-transplant(Days 100 post-transplant)
- Participants With Maximum Stage of Upper GI at Day 100 Post-transplant(Day 100 post-transplant)
- Number of Participants Experiencing Chronic GVHD With Maximum Severity at 12 Months Post-transplant(12 months post-transplant)
- Percentage of Participants With Lymphocyte Recovery Post-transplant(Day 60, Day 100, 6 Months, and 1 year post-transplant)
- Percentage of Participants With Disease Relapse at 1 Year Post-transplant(1 year post-transplant)
- Participants With Maximum Acute GVHD at One Year Post-transplant(One year post-transplant)
- Percentage of Participants With Platelet Recovery Post-transplant(Day 60 and Day 100 post-transplant)
- Number of Participants Reporting Grade 3-5 Toxicities by 1 Year Post-transplant(1 year post-transplant)
- Percentage of Participants With Lymphoproliferative Disease (PTLD) at 1 Year Post-Transplant(1 year Post-Transplant)
- Percentage of Participants With Chronic GVHD Post-transplant(6, 12 months post-transplant)
- Number of Participants With Immunosuppression-Free Survival (ISFS) at 1 Year Post-transplant(1 year post-transplant)
- Percentage of Participants With Neutrophil Recovery Post-transplant(Days 28 and day 100 post-transplant)
- Summary Statistics for Donor Chimerism(Day 28 and Day 100 post-transplant)
- Number of Participants With Grade 2 and 3 Infections(1 year post-transplant)
- Percentage of Participants With CMV at Day 100 Post-transplant(Day 100 post-transplant)
- Percentage of Participants With Disease-Free Survival (DFS) at 1 Year Post-transplant(1 year post-transplant)
- Percentage of Participants With Immunosuppression-Free Survival (ISFS) at 1 Year Post-transplant(1 year post-transplant)
- Number of Participants With Each Level of Donor Cell Engraftment Post-transplant(Day 28 and Day 100 post-transplant)
- Percentage of Participants With Overall Survival (OS) at 1 Year Post-transplant(1 year post-transplant)
- Percentage of Participants With Treatment-related Mortality (TRM) Post-transplant(Days 100, 180 and 1 year post-transplant)
- Percentage of Participants With Grade 2 and 3 Infections(6 months and 1 year post-transplant)